Defactinib (VS-6063) Mechanism of Action: FAK Inhibition in Ovarian Cancer Cell Research

Defactinib (VS-6063) MOA:Targeting FAK/RAS-MAPK Signaling Pathway for Low-Grade Serous Ovarian Cancer

🎯 check Defactinib (VS-6063) product page

Defactinib (VS-6063) is a potent, selective FAK and Pyk2 inhibitor. It affects FAK/Src and RAS/MAPK signaling pathways by blocking FAK phosphorylation at Y397/Y925, thereby inhibiting tumor cell proliferation, migration, and invasion.

Primary Applications and Mechanism of Action